SecBot SecBot
PRESS-RELEASE ·Filed Jul 17, 2026

RGNX

REGENXBIO Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed4mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The offering will dilute existing shareholders by ~17-20%, likely pressuring the stock near term. Monitor for potential additional dilution if underwriters exercise the greenshoe option. The increased cash runway supports ongoing clinical programs (RGX-202, ABBV-RGX-314, NAVSUNLI) but does not change the fundamental risk profile.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

RGNX drug pipeline →

surabgene lomparvovec

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
Next catalyst
None dated

What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.89
T+0 close · Jul 17, 2026 · via day close
Latest settled
−21.44%
T+60 · $7.77
Vs SPY
−26.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 17 $9.89entry
  2. T+1 · 4mo ago +4.35%α +4.51% · $10.32
  3. T+5 · 4mo ago +3.64%α +4.33% · $10.25
  4. T+20 · 3mo ago +8.85%α +4.40% · $10.77
  5. T+60 · 5w ago −21.44%α −26.12% · $7.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, representing ~17-20% dilution of existing shares. The offering closes July 20, with underwriters holding a 30-day option for an additional 1.67M shares. This capital raise provides cash runway but significantly dilutes current holders.

Key Financial Metrics

Deal Value
$100.0M

Key Facts

  • Gross proceeds of ~$100M from 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
  • Underwriters have 30-day option to purchase an additional 1,667,250 shares
  • Offering expected to close July 20, 2026
  • Joint book-runners: Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho
  • Dilution of ~17-20% based on market cap of $579M at $9.00/share

Financial Impact

$100M gross proceeds with ~17-20% dilution of outstanding shares

dilutioncash positionshare count

Risk Factors

  • Further dilution if underwriters exercise the 30-day option for 1.67M additional shares
  • Stock price may decline as new shares enter the market and existing holders absorb dilution
  • No specific use of proceeds disclosed, raising uncertainty about capital allocation efficiency

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302828273

Track record

15 reports on RGNX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026